Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 (MT-ND3) is a core subunit of respiratory chain complex I, the largest enzyme complex of the mitochondrial electron transport system. MT-ND3 is essential for the catalytic activity of complex I, which transfers electrons from NADH to ubiquinone, contributing to the generation of the proton gradient and ATP synthesis in mitochondria. Variants in MT-ND3 cause inherited mitochondrial diseases such as Leigh syndrome and Leber hereditary optic neuropathy and are implicated in Parkinson's disease. MT-ND3 itself is not a classic drug target, but is crucial in the function and dysfunction of the mitochondrial respiratory chain, and is important for diagnosis and study of mitochondrial diseases.
Inhibition of mitochondrial respiratory chain complex I, disruption of electron transport, and reduction of NADH oxidation can occur with inhibitors of complex I (e.g., rotenone acts by direct inhibition of site within complex I)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 (MT-ND3).